Health Care Reform and Business Development: 10 Reasons it Matters
This article was originally published in RPM Report
The drama of the health care reform debate is undeniable, but that doesn’t mean it’s easy to see how it will change the business of drug development. But it will, and we’ll give you 10 reasons why.
You may also be interested in...
After implementing a major workforce reduction in January, Abbott Laboratories re-organized its diversified company into three units – proprietary pharmaceuticals, durable growth products and innovation-driven devices. Its latest announcement cements that change: Abbott will divide into a diversified medical products company.
Abbott’s decision to spin-off proprietary pharmaceuticals as a stand-alone company is all about Wall Street: investors cheered the move for “unlocking value” by removing the giant shadow cast by Humira over the diversified base business. But it is also an important touchstone for all the key public policy themes playing out in the biopharma space after health care reform.
How Wall Street’s reaction to the impact of health care reform may help the pharmaceutical industry make sure it pays off in the long run.